Literature DB >> 22798281

Successful use of low molecular weight heparin in intracardiac thrombus of an extremely low birth weight infant.

Ji-hye Shin1, Gee-na Kim, Hong-ryang Kil, Mea-young Chang.   

Abstract

The sick premature infants have high risk for thrombosis. Although therapeutic options include close observation, anticoagulation, thrombolytic therapy, and thrombectomy, guidelines for the management of neonatal arterial and venous thrombosis vary greatly among different centers. The authors report their experience using low molecular weight heparin (enoxaparin), with safe and successful resolution of right atrial thrombus, in an extremely low birth weight infant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22798281     DOI: 10.1007/s12098-012-0840-7

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  5 in total

Review 1.  The evaluation and management of postnatal thromboses.

Authors:  M A Saxonhouse; D J Burchfield
Journal:  J Perinatol       Date:  2009-03-12       Impact factor: 2.521

2.  Neonatal symptomatic thromboembolism in Germany: two year survey.

Authors:  U Nowak-Göttl; R von Kries; U Göbel
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-05       Impact factor: 5.747

Review 3.  Successful use of tissue plasminogen activator in catheter-related intracardiac thrombus of a premature infant.

Authors:  M J Torres-Valdivieso; J Cobas; C Barrio; C Muñoz; M Pascual; C Orbea; E Rodriguez; F Gutiérrez
Journal:  Am J Perinatol       Date:  2003-02       Impact factor: 1.862

4.  Neonatal thrombosis: report of a prospective Canadian and international registry.

Authors:  B Schmidt; M Andrew
Journal:  Pediatrics       Date:  1995-11       Impact factor: 7.124

Review 5.  Thrombosis in the critically ill neonate: incidence, diagnosis, and management.

Authors:  Alex Veldman; Marcel F Nold; Ina Michel-Behnke
Journal:  Vasc Health Risk Manag       Date:  2008
  5 in total
  1 in total

1.  Stability and Sterility of Enoxaparin 8 mg/mL Subcutaneous Injectable Solution.

Authors:  Brady S Moffett; Kimberly Dinh; Jennifer Placencia; Gregory Pelkey; Shiu-Ki Rocky Hui; Jun Teruya
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jul-Aug
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.